--- title: "Q32 Bio (QTTB) news: offering and Nasdaq notice" url: "https://aibio.space/companies/q32-bio/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "QTTB offering and Nasdaq notice news: Q32 Bio reports Q2 2026 net loss of $8.9 million and $106.3 million cash. Q32 Bio Inc. (NASDAQ: QTTB), United States." --- QTTB Q32 Bio Inc. NASDAQ · United States # Q32 Bio (QTTB) news QTTB offering and Nasdaq notice news Company Updates · 2026-09-30 ## [Q32 Bio reports Week 36 SIGNAL-AA Part B results for bempikibart](https://aibio.space/news/q32-bio-reports-week-36-signal-aa-part-b-results-bempikibart/) Bempikibart showed a 35.3% mean reduction in SALT score at Week 36 in alopecia areata. The company intends to start a registration-directed program in the first half of 2027. ## Latest Q32 Bio news 1. 2026-09-14 Company Updates [Q32 Bio appoints José Trevejo as chief medical officer and Ellie Hershberger as chief development officer](https://aibio.space/news/q32-bio-appoints-jose-trevejo-chief-medical-officer-ellie-hershberger/) Both hires come as Q32 Bio prepares a registration-directed program for bempikibart in alopecia areata. The company plans to start it in the first half of 2027. 2. 2026-08-05 Company Updates [Q32 Bio reports Q2 2026 net loss of $8.9 million and $106.3 million cash](https://aibio.space/news/q32-bio-reports-q2-2026-net-loss-8-9-million-106-3-million-cash/) The company reported positive 36-week topline results for bempikibart and completed a $200.0 million public offering in July 2026. 3. 2026-07-14 Financings [Q32 Bio enters underwriting agreement for public offering at $18.25 per share](https://aibio.space/news/q32-bio-enters-underwriting-agreement-public-offering-18-25-share/) Morgan Stanley, Jefferies, Cantor Fitzgerald and Oppenheimer are the representatives of the underwriters. The offering is expected to close on July 16, 2026. 4. 2026-05-05 Company Updates [Q32 Bio reports Q1 2026 results and first patient dosed in Part B extension](https://aibio.space/news/q32-bio-reports-q1-2026-results-first-patient-dosed-part-b-extension/) Cash and cash equivalents were $50.8 million at March 31, 2026. The company received $14.2 million of at-the-market proceeds after the quarter ended. 5. 2025-12-01 Mergers [Q32 Bio sells ADX-097 to Akebia Therapeutics for $7.0 million upfront](https://aibio.space/news/q32-bio-sells-adx-097-akebia-therapeutics-7-0-million-upfront/) Q32 Bio closed the asset sale on November 28, 2025 and is eligible for up to $580 million in milestones plus royalties. It now expects cash to fund operations into the second half of 2027. 6. 2025-05-23 Listings [Q32 Bio gets Nasdaq notice after reporting stockholders' deficit of ($4.0 million)](https://aibio.space/news/q32-bio-gets-nasdaq-notice-after-reporting-stockholders-deficit-4-0/) The minimum stockholders' equity requirement is $2.5 million. Q32 Bio has 45 calendar days to submit a plan to regain compliance. 7. 2025-02-10 Distress [Q32 Bio announces restructuring and workforce reduction to focus on bempikibart](https://aibio.space/news/q32-bio-announces-restructuring-workforce-reduction-focus-bempikibart/) Q32 Bio is ending its renal trial of ADX-097, cutting staff and betting on bempikibart in alopecia areata. It expects about $1.1 million in severance charges and says cash should last into the second half of 2026, but the release gives no cash balance. ## Q32 Bio at a glance - **Ticker**: QTTB - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $106.3 million ### Related companies - [Cartesian Therapeutics](https://aibio.space/companies/cartesian-therapeutics/) NASDAQ: RNAC - [Anavex Life Sciences](https://aibio.space/companies/anavex-life-sciences/) NASDAQ: AVXL - [Palvella Therapeutics](https://aibio.space/companies/palvella-therapeutics/) NASDAQ: PVLA - [Iovance Biotherapeutics](https://aibio.space/companies/iovance-biotherapeutics/) NASDAQ: IOVA - [BANGI INC](https://aibio.space/companies/bangi/) OTC: BNGI - [Lyell Immunopharma](https://aibio.space/companies/lyell-immunopharma/) NASDAQ: LYEL - [Vaxart](https://aibio.space/companies/vaxart/) OTC: VXRT - [GB Sciences](https://aibio.space/companies/gb-sciences/) OTC: GBLX ### Also on NASDAQ - [Ironwood Pharmaceuticals](https://aibio.space/companies/ironwood-pharmaceuticals/) IRWD - [Savara](https://aibio.space/companies/savara/) SVRA - [Attovia Therapeutics](https://aibio.space/companies/attovia-therapeutics/) ATTO - [NRC HEALTH](https://aibio.space/companies/nrc-health/) NRC - [Celularity](https://aibio.space/companies/celularity/) CELU - [Processa Pharmaceuticals](https://aibio.space/companies/processa-pharmaceuticals/) PCSA ## Q32 Bio annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$53.7 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | [$0](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | | Research and development | [$19.2 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | [$48.1 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | | Net income (loss) | [$29.8 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | [-$47.7 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | | Cash from operations | [-$33.5 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | [-$67.7 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | | Cash and equivalents | [$48.3 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526333831/) | [$78.0 million](https://www.sec.gov/Archives/edgar/data/1661998/000119312526099339/) | | Short-term investments | | [$0](https://www.sec.gov/Archives/edgar/data/1661998/000095017025036823/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $106.3 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Q32 Bio Has Q32 Bio raised money recently? Our latest story on this, dated Aug 5, 2026: "Q32 Bio reports Q2 2026 net loss of $8.9 million and $106.3 million cash". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/q32-bio-reports-q2-2026-net-loss-8-9-million-106-3-million-cash/). Has Q32 Bio received a Nasdaq deficiency notice? Our latest story on this, dated May 23, 2025: "Q32 Bio gets Nasdaq notice after reporting stockholders' deficit of ($4.0 million)". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/q32-bio-gets-nasdaq-notice-after-reporting-stockholders-deficit-4-0/). What is the ticker symbol of Q32 Bio? Q32 Bio Inc. trades under the ticker QTTB on NASDAQ. Where is Q32 Bio listed? Q32 Bio Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:DB0; LSE:0T6G. What is the SEC CIK of Q32 Bio? The SEC Central Index Key (CIK) for Q32 Bio Inc. is 1661998. Its filings are on SEC EDGAR. How many shares does Q32 Bio have outstanding? 29,769,466 shares as of 2026-08-03, per the cover page of its 10-Q filed 2026-08-05. Which country or territory is Q32 Bio listed under? Our directory records Q32 Bio Inc. under United States. What does Q32 Bio do? Our directory classifies Q32 Bio Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Q32 Bio? The ISIN recorded for Q32 Bio Inc. is US7469641051. Does aibio.space cover Q32 Bio? aibio.space lists Q32 Bio Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Q32 Bio incorporated? SEC records list its state or country of incorporation as DE. What was Q32 Bio's revenue last year? $53.7 million for the fiscal year ended Dec 31, 2025, as reported to the SEC. Is Q32 Bio profitable? Q32 Bio Inc. reported net income of $29.8 million for the fiscal year ended Dec 31, 2025, and used $33.5 million of cash in operations, per its annual report to the SEC. How much does Q32 Bio spend on research and development? $19.2 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Q32 Bio have? $106.3 million in cash at Jun 30, 2026, per its 10-Q. ## Investor discussion: Q32 Bio Members talk about Q32 Bio (QTTB). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Q32 Bio, newest first. Each line links the filing it comes from. 1. 2026-09-14 Financings Reported a financing. SEC Form 8-K (Items 7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/d158730dex991.htm) 2. 2026-07-13 Financings Filed a final prospectus for a securities offering. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312526302100/d119567d424b5.htm) 3. 2026-05-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312526241846/d228038dex991.htm) 4. 2026-04-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312526177170/d28103d424b5.htm) 5. 2026-03-27 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312526129424/d58441d424b5.htm) 6. 2026-02-17 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312526054660/d92489d424b5.htm) 7. 2025-12-01 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,1.02,2.01,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312525303115/d70163dex991.htm) 8. 2025-05-23 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1661998/000119312525125435/d842247d8k.htm) 9. 2025-02-10 Distress Reported a restructuring, a workforce reduction or a review of strategic alternatives. SEC Form 8-K (Items 2.05,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1661998/000095017025017075/qttb-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:QTTB on TradingView](https://www.tradingview.com/symbols/NASDAQ-QTTB/). ## SEC filings and registration - **SEC name**: Q32 Bio Inc. - **CIK**: 1661998 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: QTTB (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 830 WINTER STREET, WALTHAM, MA, 02451 - **Phone**: 781-999-0232 - **Shares outstanding**: 29,769,466 as of 2026-08-03 (10-Q filed 2026-08-05) - **Former names**: Q32 Bio Inc.; Homology Medicines, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1661998/000119312526408435/d13352d8k.htm) filed 2026-09-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1661998/000119312526389836/d158730d8k.htm) filed 2026-09-14 - [10-Q](https://www.sec.gov/Archives/edgar/data/1661998/000119312526333831/qttb-20260630.htm) filed 2026-08-05 - [8-K](https://www.sec.gov/Archives/edgar/data/1661998/000119312526333813/qttb-20260805.htm) filed 2026-08-05 - [S-3](https://www.sec.gov/Archives/edgar/data/1661998/000119312526307835/d156763ds3.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1661998/000119312526304964/d150730d8k.htm) filed 2026-07-15 - [424B5](https://www.sec.gov/Archives/edgar/data/1661998/000119312526304946/d119567d424b5.htm) filed 2026-07-15 - [424B5](https://www.sec.gov/Archives/edgar/data/1661998/000119312526302100/d119567d424b5.htm) filed 2026-07-13 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001661998), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Q32 Bio Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker QTTB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Q32 Bio Inc. - **Ticker**: QTTB - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US7469641051 - **Other listed symbols**: GETTEX:DB0; LSE:0T6G - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-QTTB/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/q32-bio/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Q32 Bio (QTTB) news: offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/q32-bio/